Spectrum Pharma (SPPI) Misses Q1 EPS by 1c

Spectrum Pharma (NASDAQ: SPPI) reported Q1 EPS of ($0.36), $0.01 worse than the analyst estimate of ($0.35).

“The progress in our development pipeline speaks to the investigator interest and the commitment of our team during these unprecedented times,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. “The PDUFA date for ROLONTIS remains October 24, 2020 and our updated poziotinib strategy is well under way. We continue to drive the business forward and remain focused on achieving our milestones this year.”

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance
• NextEra Energy (NEE) Tops Q1 EPS by 16c, provides guidance
• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance